These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 25112128)

  • 1. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is regional nodes radiotherapy an alternative to surgery?
    Offersen BV; Nielsen HM; Overgaard M; Overgaard J
    Breast; 2013 Aug; 22 Suppl 2():S118-28. PubMed ID: 24074772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
    J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
    Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
    Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
    Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
    J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
    Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
    Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative axillary surgery in breast cancer patients undergoing mastectomy: long-term results.
    Cowher MS; Grobmyer SR; Lyons J; O'Rourke C; Baynes D; Crowe JP
    J Am Coll Surg; 2014 Apr; 218(4):819-24. PubMed ID: 24655877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
    Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
    Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the number of sentinel lymph nodes harvested with survival in breast cancer.
    Bonneau C; Bendifallah S; Reyal F; Rossi L; Rouzier R
    Eur J Surg Oncol; 2015 Jan; 41(1):52-8. PubMed ID: 25466979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of axillary disease.
    Caudle AS; Cupp JA; Kuerer HM
    Surg Oncol Clin N Am; 2014 Jul; 23(3):473-86. PubMed ID: 24882346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omission of axillary lymph node dissection for clinically node negative early-stage breast cancer patients.
    Kobayashi R; Shiraishi K; Iwase S; Ohtomo K; Nakagawa K
    Breast Cancer; 2015 Nov; 22(6):657-63. PubMed ID: 24756246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
    Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
    Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Regional Nodal Management of Breast Cancer Patients with Low Nodal Burden.
    Raber BM; Lin H; Shen Y; Shaitelman SF; Bedrosian I
    Ann Surg Oncol; 2019 Dec; 26(13):4346-4354. PubMed ID: 31605340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011.
    Krishnan MS; Recht A; Bellon JR; Punglia RS
    Breast Cancer Res Treat; 2013 Feb; 138(1):205-13. PubMed ID: 23338762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).
    Park Y; Shin YS; Kim K; Shin KH; Chang JH; Kim SS; Jung JH; Park W; Kim H; Kim YB; Ahn SJ; Kim M; Kim JH; Cha HJ; Kim TG; Park HJ; Lee SY
    Eur J Surg Oncol; 2023 Mar; 49(3):589-596. PubMed ID: 36470801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.